Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Alkermes plc. Director's Dealing 2025

Feb 1, 2025

31048_dirs_2025-01-31_f5691199-34b1-4ba6-adfb-9b8b7e0fbac6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alkermes plc. (ALKS)
CIK: 0001520262
Period of Report: 2025-01-30

Reporting Person: Hopkinson Craig C. (EVP R&D, Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-01-30 Ordinary Shares M 29156 $20.03 Acquired 76732 Direct
2025-01-30 Ordinary Shares M 26589 $19.34 Acquired 103321 Direct
2025-01-30 Ordinary Shares M 23542 $24.59 Acquired 126863 Direct
2025-01-30 Ordinary Shares M 18345 $26.82 Acquired 145208 Direct
2025-01-30 Ordinary Shares S 100918 $32.0496 Disposed 44290 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-01-30 Employee Stock Option (Right to Buy) $20.03 M 29156 Disposed 2030-02-20 Ordinary Shares (29156) Direct
2025-01-30 Employee Stock Option (Right to Buy) $19.34 M 26589 Disposed 2031-02-22 Ordinary Shares (26589) Direct
2025-01-30 Employee Stock Option (Right to Buy) $24.59 M 23542 Disposed 2032-02-18 Ordinary Shares (23542) Direct
2025-01-30 Employee Stock Option (Right to Buy) $26.82 M 18345 Disposed 2033-02-23 Ordinary Shares (18345) Direct

Footnotes

F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.17. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

F4: These options are fully vested in accordance with their terms.

F5: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

F6: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

F7: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.